Final FDA bill lacks new DTC oversight

The Senate overwhelmingly passed the drug-safety and FDA funding bill yesterday and sent it along to President Bush for his signature. Experts are calling it a sea change in the FDA's operations. Instead of waiting for reports of adverse events to roll in, the agency will be on the prowl for evidence--digitally, through its new surveillance system and clinical trials database, and non-digitally, by ordering post-approval trials. Questions: Will the agency figure out how to separate false alarms from real read flags? Can it target its post-approval trials appropriately? There's nothing to do but watch and wait.

Interestingly, the final version of the bill is a bit toothless when it comes to regulating drug ads. Apparently, the media industry helped pharma fight provisions that would have allowed the FDA to force changes in direct-to-consumer advertising. Now, the agency will only be able to recommend them.

- read the analysis in the Los Angeles Times
- read this Wall Street Journal article on the media's pro-DTC lobbying

Related Articles:
House overhauls, passes PDUFA. Report
FDA: 2,000 layoffs if PDUFA not passed. Report
Bickering may stall trial database. Report
10 reforms for drug advertising. Report
Does the FDA do enough to regulate drug ads? Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.